Treatment for lipodystrophy

Abstract

The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

1 - 32 . (canceled) 
     
     
         33 . A pharmaceutical composition comprising:
 a compound of formula (I)   
       
         
           
           
               
               
           
         
       
       wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg; and
 a pharmaceutically acceptable excipient. 
 
     
     
         34 . The pharmaceutical composition of  claim 33 , wherein the compound of formula (I) is present in an amount between about 1 mg to about 250 mg. 
     
     
         35 . The pharmaceutical composition of  claim 33 , wherein the compound of formula (I) is present in an amount between about 4 mg to about 50 mg. 
     
     
         36 . The pharmaceutical composition of  claim 33 , wherein the pharmaceutical composition is suitable to be administered orally, intravenously, or parenterally. 
     
     
         37 . A pharmaceutical composition comprising:
 a) a compound of formula (I)   
       
         
           
           
               
               
           
         
       
       wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg;
 b) a buffering agent; 
 c) a stabilizer; 
 d) optionally a second therapeutic agent; and 
 e) optionally one or more pharmaceutically acceptable excipients. 
 
     
     
         38 . The pharmaceutical composition of  claim 37 , wherein the compound of formula (I) is present in an amount between about 1 mg to about 250 mg. 
     
     
         39 . The pharmaceutical composition of  claim 37 , wherein the compound of formula (I) is present in an amount between about 4 mg to about 50 mg. 
     
     
         40 . The pharmaceutical composition of  claim 37 , wherein the buffering agent is selected from the group consisting of sodium acetate, ammonia solution, ammonium carbonate, sodium borate, adipic acid, glycine, and monosodium glutamate. 
     
     
         41 . The pharmaceutical composition of  claim 37 , wherein the stabilizer is selected from the group consisting of polacrilin potassium, potassium chloride, and sodium stearyl fumarate. 
     
     
         42 . The pharmaceutical composition of  claim 37 , wherein the one or more pharmaceutically acceptable excipients is selected from the group consisting of a carrier, a binder, an antioxidant agent, a disintegrating agent, a wetting agent, a lubricating agent, a chelating agent, and a surface active agent. 
     
     
         43 . The pharmaceutical composition of  claim 37 , wherein the pharmaceutical composition is suitable to be administered orally, intravenously, or parenterally. 
     
     
         44 . A pharmaceutical composition comprising:
 i) a compound of formula (I)   
       
         
           
           
               
               
           
         
       
       wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg; and
 ii) a second therapeutic agent, 
 wherein the second therapeutic agent is selected from the group consisting of an agent used to control blood glucose levels, an agent used to control lipid levels, an antioxidant, an appetite suppressing agent, an anti-obesity agent, an antibiotic, a probiotic, and an anti-inflammatory agent. 
 
     
     
         45 . The pharmaceutical composition of  claim 44 , wherein the compound of formula (I) is present in an amount between about 1 mg to about 250 mg. 
     
     
         46 . The pharmaceutical composition of  claim 44 , wherein the compound of formula (I) is present in an amount between about 4 mg to about 50 mg. 
     
     
         47 . The pharmaceutical composition of  claim 44 , wherein the pharmaceutical composition is suitable to be administered orally, intravenously, or parenterally.